Alpha-glucosidase is an enzyme that is inhibited by alpha-glucosidase inhibitor drugs. Alpha-glucosidase helps in absorption of carbohydrates by breaking down carbohydrates into tiny sugar molecules such as glucose. The inhibition is reversible, and competitive inhibition. Alpha-glucosidase inhibitor drugs help in delaying glucose absorption and slow the digestion of carbohydrates. This results in lower rise of glucose in the blood after meals and remains effective throughout the day.
Alpha-glucosidase inhibitor drugs help in the treatment of dumping syndrome and type 2 diabetes. Dumping syndrome is a disease in which the food in the stomach is emptied rapidly into the small intestine. This results in drawing excess of fluid from the partially digested food into the small intestine that causes palpitations, faintness, sweating, diarrhea, cramping, and nausea. Dumping syndrome normally occurs in people who consume excess of refined or simple sugar, specifically in the people who had surgery done to remove or modify the stomach. Type 2 diabetes is also known as insulin resistance due to body cells not being able to respond appropriately in the presence of hormone insulin. It is more complex than type 1 diabetes, however, it is sometimes easier to treat. Undiagnosed type 2 diabetes, may cause severe complications that include coronary artery disease and renal failure.
Growth in geriatric population across the world boosts the demand for alpha-glucosidase inhibitor drugs as elderly people are more prone to diseases such as type 2 diabetes. Furthermore, rising disposable income increases the demand for alpha-glucosidase inhibitor drugs. Sedentary lifestyle of people and changing environmental conditions are the drivers of the global alpha-glucosidase inhibitor drugs market. Moreover, strong inheritable genetic connection in type 2 diabetes propels the market for alpha-glucosidase inhibitor drugs. Increasing cases in obesity and chronic obesity also leads to chances of development of type 2 diabetes, which in turn, drives the growth of the global alpha-glucosidase inhibitor drugs market. Increasing stomach surgeries due to stomach cancer boosts the demand for the alpha-glucosidase inhibitor drugs. According to the World Health Organization (WHO), in 2015, there were 754000 deaths due to stomach cancer.
The global alpha-glucosidase inhibitor drugs market can be segmented on the basis of disease type, distribution channel, and region. Based on disease type, the global alpha-glucosidase inhibitor drugs market can be categorized into dumping syndrome and type 2 diabetes. In terms of the distribution channel, the global alpha-glucosidase inhibitor drugs market can be divided into online pharmacies, retail pharmacies, and hospital pharmacies.
Geographically, the global alpha-glucosidase inhibitor drugs market can be divided into Latin America, Asia Pacific, Europe, North America, and Middle East & Africa. North America constituted a major share of the alpha-glucosidase inhibitor drugs market in 2016 due to increasing prevalence of type 2 diabetes in the region. According to researches, more than 95% of the population in North America is suffering from type 2 diabetes and approximately 20% of this population is over the age of 65. Europe accounted for the next leading share of the alpha-glucosidase inhibitor drugs market in 2016 due to increasing disposable income and high investments in research and development of alpha-glucosidase inhibitor drugs in the region. The alpha-glucosidase inhibitor drugs in Asia Pacific is anticipated to expand during the forecast period owing to increasing awareness about alpha-glucosidase inhibitor drugs, and investments made by key players to penetrate the emerging countries of the region, especially India and China. The alpha-glucosidase inhibitor drugs market in Latin America and Middle East & Africa is also expected to expand during the forecast period owing to increasing government initiatives in the regions.
Key players of the global alpha-glucosidase inhibitor drugs market include Pfizer Inc. and Bayer AG.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
The regional analysis covers:
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Please fill the Request TOC form below.
Make an enquiry before buying this Report
Please fill the enquiry form below.